Phase 3 Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be a woman aged 18 or older.
- If you are of childbearing age, you must have a negative pregnancy blood test at the start of the study and agree to use an approved form of contraception during the study and for 12 weeks after treatment ends.
- If you are postmenopausal (naturally or due to surgery), you must meet at least one of these conditions: you have had both ovaries removed, you are 60 or older, or you are under 60 with no periods for at least 12 months and hormone levels confirming menopause.
- You must have been diagnosed with a specific stage of cervical cancer (Stage IB2), confirmed by a tissue sample showing one of three cell types: squamous cell, adenocarcinoma, or adenosquamous.
- You must be a candidate for combined chemotherapy and radiation treatment.
- You must have a general health status rated as ECOG 0–2, meaning you are able to carry out daily activities with little to no limitation (confirm with trial site).
- Your cancer must be measurable on CT scan and pelvic MRI scans according to standard measurement guidelines.
- You must not have received any previous treatment for this cancer.
- Your kidneys must be functioning well enough, with a specific kidney function score of 60 or above (confirm with trial site).
- Your blood counts and liver function must meet certain minimum levels, including red blood cells, white blood cells, platelets, and liver markers — a blood transfusion before treatment is allowed if needed to reach the required levels.
- You must have signed a consent form agreeing to take part in the study.
- If you have certain existing health conditions, you may still be eligible, including well-controlled Type 2 diabetes, mild to moderate high blood pressure, mild liver disease, treated and stable heart disease without symptoms, mild heart failure, or mild/inactive lupus.
Who may not be able to join:
- You have been diagnosed with a second type of cancer.
- You are pregnant or currently breastfeeding.
- Your cervical cancer is of a specific rare type called small cell or neuroendocrine.
- Your kidneys are not functioning well enough (below the required threshold).
- You have a history of active tuberculosis (TB).
- You have a history of HIV infection.
- You have abnormal connections (fistulas) between your bladder and vagina or bladder and rectum at the time of diagnosis.
- You are currently taking part in another experimental drug study.
- Your personal, family, or location circumstances suggest you may have difficulty consistently attending or following the study requirements (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Eder A Arango, MD, National Cancer Institute of Mexico
Phone: +5215531952791
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To assess the efficacy of concomitant chemoradiotherapy with gemcitabine versus cisplatin in patients with locally advanced cervical cancer (stages IB2-IVA), who have comorbidities and preserved renal function, with progression-free survival rate.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.